Overweight and hypertension: A 2-way street?

Hypertension

Volumn 35, Issue 3, 2000, Pages 807-813

  Julius, Stevo ^a,c   Valentini, Mariaconsuelo ^a   Palatini, Paolo ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adrenergic receptors; Hypertension, obesity; Obesity; Sympathetic nervous system

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADRENERGIC SYSTEM; ARTICLE; CARDIOVASCULAR RESPONSE; DIETARY INTAKE; ENERGY METABOLISM; HUMAN; HYPERTENSION; OBESITY; PRIORITY JOURNAL; SYMPATHETIC TONE; WEIGHT GAIN;

EID: 0034060897     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.3.807     Document Type: Article

References (71)

1. Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure: findings in hypertension screening of 1 million Americans. JAMA. 1978;240:1607-1610.
2. Cassono PA, Segal MR, Vokonas PS, Weiss ST. Body fat distribution, blood pressure, and hypertension: a prospective cohort study of men in the normative aging study. Ann Epidemiol. 1990;1:33-48.
3. Kannel WB, Brand N, Skinner JJ Jr, Dawber TR, McNamara PM. The relation of adiposity to blood pressure and development of hypertension. Ann Intern Med. 1967;67:48-59.
4. MacMahon S, Cutler J, Brittain E, Higgins M. Obesity and hypertension: epidemiological and clinical issues. Eur Heart J. 1987;8(suppl B):57-70.
5. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med. 1986;61:1081-1090.
6. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
7. Young JB, Landsberg L. Suppression of sympathetic nervous system during fasting. Science. 1977;196:1473-1475.
8. Young JB, Landsberg L. Stimulation of the sympathetic nervous system during sucrose feeding. Nature. 1977;269:615-617.
9. Narkiewicz K, Somers VK, Mos L, Kato M, Accurso V, Palatini P. An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension. J Hypertens. 1999;17: 245-249.
10. Campese VM, Romoff MS, Levitan D, Saglikes Y, Friedler RM, Massry SG. Abnormal relationship between sodium intake and sympathetic nervous system activity in salt-sensitive patients with essential hypertension. Kidney Int. 1982;21:371-378.
11. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure Study. JAMA. 1990;264: 354-358.
12. Julius S, Krause L, Schork N, Mejia A, Jones K, van de Ven C, Johnson E, Sekkarie MA, Kjeldsen SE, Petrin J, Schmouder R, Gupta R, Ferraro J, Nazzaro P, Weissfeld J. Hyperkinetic borderline hypertension in Tecumseh, Michigan. J Hyperrens. 1991;9:77-84.
13. Palatini P, Vriz O, Nesbitt S, Amerena J, Majahalme S, Valentini M, Julius S. Parental hyperdynamic circulation predicts insulin resistance in offspring: the Tecumseh Offspring Study. Hypertension. 1999;33: 769-774.
14. Wassertheil-Smoller S, Blaufox MD, Oberman AS, Langford HG, Davis BR, Wylie-Rosett J. The Trial of Antihypertensive Interventions and Management (TAIM) study: adequate weight loss, alone and combined with drug therapy in the treatment of mild hypertension. Arch Intern Med. 1992;152:131-136.
15. Lasser VI, Raczynski JM, Stevens VJ, Mattfeldt-Beman MK, Kumanyika S, Evans M, Danielson E, Dalcin A, Batey DM, Beiden LK, et al: Trials of hypertension prevention, phase II: structure and content of the weight loss and dietary sodium reduction interventions: Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Ann Epidemiol. 1995; 5:156-164.
16. Elmer PJ, Grimm R Jr, Laing B, Grandits G, Svendsen K, Van Heel N, Betz E, Raines J, Link M, Stamler J, et al: Lifestyle intervention: results of the Treatment of Mild Hypertension Study (TOMHS). Prevent Med. 1995;24:378-388.
17. Rosenbaum M, Leibel RJ, Hirsch J. Obesity. N Engl J Med. 1997;337: 396-407. (Correction. 1998;338:555.)
18. Scherrer U, Randin D, Tappy L, Vollenweider MD, Jequier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994;89:2634-2640.
19. Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation. 1971;44: 413-418.
20. Goldstein DS. Plasma catecholamines and essential hypertension: an analytical review. Hypertension. 1983;5:86-99.
21. Esler M, Ferner C, Lambert G, Eisenhofer G, Cox H, Jennings G. Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension. 1991;17(suppl III):III-29-III-35.
22. Kjeldsen SE, Zweifler AJ, Petrin J, Weder AB. Julius S. Sympathetic nervous system involvement in essential hypertension: increased platelet noradrenaline coincides with decreased β-adrenoreceptor responsiveness. Blood Pressure. 1994;3:164-171.
23. Esler M, Lambert G, Vaz M, Thompson J, Kaye D, Kalff V, Kelly M, Turner A, Jennings G. Central nervous system monoamine neurotransmitter turnover in primary and obesity-related human hypertension. Clin Exp Hypertens. 1997;19:577-590.
24. Guzzetti S, Piccaluga E, Casati R, Cerutti S, Lombardi F, Pagani M, Malliani A. Sympathetic predominance in essential hypertension: a study employing spectral analysis of heart rate variability. J Hypertens. 1988; 6:711-717.
25. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: evidence from direct intraneural recordings. Hypertension. 1989;14:177-183.
26. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68-72.
27. Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension. 1997;30:1267-1273.
28. Julius S, Gudbrandsson T, Jamerson K, Shahab ST, Andersson O. Hypothesis: the hemodynamic link between insulin resistance and hypertension. J Hypertens. 1991;9:983-986.
29. Tataranni PA. From physiology to neuroendocrinology: a reappraisal of risk factors of body weight gain in humans. Diabetes Metab. 1998;23: 108-115.
30. Ravussin E, Bogardus C. A brief overview of human energy metabolism and its relationship to essential obesity. Am J Clin Nutr. 1992;55(suppl): 242S-245S.
31. Landsberg L, Saville ME, Young JB. Sympathoadrenal system and regulation of thermogenesis. Am J Physiol. 1984;247:E181-E189.
32. Macdonald IA, Bennett T, Fellows IW. Catecholamines and the control of metabolism in man. Clin Sci. 1985;68:613-619. Editorial.
33. Sjostrom L, Schutz Y, Gudinchet F, Hegnell L, Pittet PG, Jequier E. Epinephrine sensitivity with respect to metabolic rate and other variables in women. Am J Physiol. 1983;245:E431-E442.
34. Welle S, Schwartz RG, Statt M. Reduced metabolic rate during β-adrenergic blockade in humans. Metabolism. 1991;40:619-622.
35. Poehlman ET, Gardner AW, Goran MI, Arciero PJ, Toth MJ, Ades PA, Calles-Escandon J. Sympathetic nervous system activity, body fatness, and body fat distribution in younger and older males. J Appl Physiol. 1995;78:802-806.
36. Paolisso G, Manzella D, Ferrara N, Gambardella A, Abete P, Tagliamonte MR, DeLucia D, Furgi G, Picone C, Gentile S, Rengo F, Varricchio M. Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. Am J Physiol. 1997;273:E471-E478.
37. Welle S, Lilavivat U, Campbelle RG. Thermic effect of feeding in man: increased plasma norepinephrine levels following glucose but not protein or fat consumption. Metab Clin Exp. 1981;30:953-958.
38. Schwartz RS, Jaeger LF, Silberstein S, Veith RC. Sympathetic nervous system activity and the thermic effect of feeding in man. Int J Obes. 1987;11:141-149.
39. Astrup A, Bulow J, Christensen NJ, Madsen J, Quaade F. Facultative thermogenesis induced by carbohydrate: a skeletal muscle component mediated by epinephrine. Am J Physiol. 1986;250:E226-E229.
40. Blaak EE, Saris WHM, van Baak MA. Adrenoceptor subtypes mediating catecholamine-induced thermogenesis in man. Int J Obes. 1993;17(suppl 3):S78-S81.
41. Acheson KJ, Ravussin E, Wahren J, Jequier E. Thermic effect of glucose in man: obligatory and facultative thermogenesis. J Clin Invest. 1984;74: 1572-1580.
42. DeFronzo RA, Thorin D, Felber JP, Simonson DC, Thiebaud D, Jequier E, Golay A. Effect of beta and alpha adrenergic blockade on glucose-induced thermogenesis in man. J Clin Invest. 1984;73:633-639.
43. 3-adrenoceptors mediate metabolic responses to isoprenaline? Q J Med. 1993;86: 595-600.
44. 3-adrenoceptor activation to epinephrine-induced thermogenesis in humans. Int J Obes. 1995;19:678-685.
45. Blaak EE, van Baak MA, Kempen KPG, Saris WHM. Role of α- and β-adrenoceptors in sympathetically mediated thermogenesis. Am J Physiol. 1993;264:E11-E17.
46. Zurlo F, Larson K, Bogardus C, Revussin E. Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest. 1990;86:1423-1427.
47. Simonsen L, Bulow J, Madsen J, Christensen NJ. Thermogenic response to epinephrine in the forearm and abdominal subcutaneous adipose tissue. Am J Physiol. 1992;263:E850-E855.
48. Astrup A, Bulow J, Madsen J, Christensen NJ. Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am J Physiol. 1985;248:E507-E515.
49. Simonsen L, Stallknecht B, Bulow J. Contribution of skeletal muscle and adipose tissue to adrenaline-induced thermogenesis in man. Int J Obes. 1993;17(suppl 3):S47-S51.
50. O'Dea K, Esler M, Leonard P, Stockigt JR, Nestel P. Noradrenaline turnover during under- and over-eating in normal weight subjects. Metab Clin Exp. 1982;31:896-899.
51. Aronne LJ, Mackintosh R, Rosenbaum M, Leibel RL, Hirsch J. Autonomic nervous system activity in weight gain and weight loss. Am J Physiol. 1995;269:R222-R225.
52. Lohse MJ. Molecular mechanisms of membrane receptor desensitization. Biochim Biophys Acta. 1993;1179:171-188.
53. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J. 1990;4: 2881-2889.
54. 3-Adrenoceptor: an update. Eur J Endocrinol. 1995;132: 377-385.
55. Messerli FH, Kuchel O, Hamet P, Tolis G, Guthrie GP Jr, Fraysse J. Nowaczynski W, Genest J. Plasma cyclic adenosine 3′:5′-monophosphate response to isoproterenol and glucagon in hyperkinetic borderline (labile) hypertension. Circ Res. 1976;38(suppl II):II-42-II-47.
56. White M, Fourney A, Leenen FHH. Age, hypertension, and cardiac responses to β-agonist in humans. Clin Pharmacol Ther. 1998;63: 663-671.
57. McAllister RG Jr, Love DW, Guthrie GP Jr, Dominic JA, Kotchen TA. Peripheral beta-receptor responsiveness in patients with essential hypertension. Arch Intern Med. 1979;139:879-881.
58. Bertel O, Buhler FR, Kiowski W, Lutold BE. Decreased beta-adrenoreceptor responsiveness as related to age, blood pressure, and plasma catecholamines in patients with essential hypertension. Hypertension. 1980;2:130-138.
59. Jennings G, Bobik A, Esler M, Korner P. Contribution of cardiovascular reflexes to differences in beta-adrenoreceptor-mediated responses in essential hypertension. Clin Sci. 1981;61(suppl 7):177s-180s.
60. Volpe M, Trimarco B, Ricciardelli B, Rengo F, Chiariello M, Cuocolo A, Ventriglia G, Veniero AM, Condorelli M. Effects of salt loading on the response to isoproterenol in normal and hypertensive subjects. Cardiologia. 1982;27:453-461.
61. Trimarco B, Volpe M, Ricciardelli B, Picotti GB, Galva MA, Petracca R, Condorelli M. Studies of the mechanisms underlying impairment of beta-adrenoceptor-mediated effects in human hypertension. Hypertension. 1983;5:584-590.
62. Julius S, Randall OS, Esler MD, Kashima T, Ellis CN, Bennett J. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. Circ Res. 1975;36/37(suppl I):I-199-I-207.
63. Julius S. Neurogenic component in borderline hypertension. In: Julius S, Esler MD, eds. The Nervous System in Arterial Hypertension. Springfield. Ill: Charles C Thomas; 1974:301-330.
64. Feldman RD. Defective venous beta-adrenergic response in borderline hypertensive subjects is corrected by a low sodium diet. J Clin Invest. 1990;85:647-652.
65. Stein CM, Nelson R, Deegan R, He H, Wood M, Wood AJ. Forearm beta adrenergic receptor-mediated vasodilation is impaired, without alteration of forearm norepinephrine spillover, in borderline hypertension. J Clin Invest. 1995;96:579-585.
66. Feldman RD, Lawton WJ, McArdle WL. Low sodium diet corrects the defect in lymphocyte beta-adrenergic responsiveness in hypertensive subjects. J Clin Invest. 1987;79:290-294.
67. Townsend RR, Klein S. Lipolytic sensitivity and response to fasting in normotensive and hypertensive obese humans. Metabolism. 1997;46: 1080-1084.
68. Lithell H, Pollare T, Berne C, Saltin B. The metabolic and circulatory response to beta-blockade in hypertensive men is correlated to muscle capillary density. Blood Pressure. 1992;1:20-26.
69. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, Honkvist P-E, Pennert K, Tuomilehto J, Wedel H, on Behalf of the Heart Attack Primary Prevention in Hypertension Trial Research Group. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens. 1987;5:561-572.
70. Rossner S, Taylor CL, Byington RP, Furberg CD. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ. 1990;300:902-903.
71. Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the 'chicken- and-egg' question. J Hypertens. 1994;12: 495-502.